About the Company
We do not have any company description for Acumen Pharmaceuticals, Inc. at the moment.
Exchange
Nasdaq
Fundamental Data and Insider Transactions (Quarterly data) Full Screen
Loading the fundamentals chart...
Latest News on Acumen Pharmaceuticals, Inc.
Acumen Pharmaceuticals, Inc. (NASDAQ:ABOS) Q2 2025 Earnings Call Transcript
Q2 2025 Earnings Call Transcript August 12, 2025 Acumen Pharmaceuticals, Inc. misses on earnings expectations. Reported EPS is $-0.68 EPS, expectations were $-0.54. Operator: Good day, and welcome to ...
Acumen Pharmaceuticals, Inc. to Present Research on Sabirnetug for ...
Acumen Pharmaceuticals, Inc. announced that it will present scientific findings related to its Alzheimer's disease treatment candidate, sabirnetug (ACU193), at two upcoming conferences: the ...
Acumen Pharmaceuticals, Inc.: Acumen Pharmaceuticals Reports Second Quarter 2025 Financial Results and Business Highlights
AD, a Phase 2 study to investigate sabirnetug (ACU193) for the treatment of early Alzheimer's disease, in late 2026Expect decision to advance an oligomer-targeted ...
Acumen Pharmaceuticals to Participate in Upcoming Investor ... - Nasdaq
--Acumen Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company developing a novel therapeutic that targets toxic soluble amyloid beta oligomers for the treatment of Alzheimer’ s ...
Acumen Pharmaceuticals Presents Studies Showing the Utility of a ...
NEWTON, Mass., July 28, 2025 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS), a clinical-stage biopharmaceutical company developing a novel therapeutic that targets soluble amyloid ...
ABOS | Acumen Pharmaceuticals Inc. Profile | MarketWatch
Acumen Pharmaceuticals Inc. 1210-1220 Washington Street Suite 210 Newton, Massachusetts 02465 Phone1 617 344-4190 IndustryPharmaceuticals SectorHealth Care/Life Sciences Fiscal Year-end12/2025 ...
Why Acumen Pharmaceuticals (ABOS) Stock Might be a Great Pick
One stock that might be an intriguing choice for investors right now is Acumen Pharmaceuticals, Inc. ABOS. This is because this security in the Medical - Biomedical and Genetics space is seeing ...
Acumen Pharmaceuticals, Inc. and Halozyme Enter Global Collaboration ...
In This Article: ABOS Acumen Pharmaceuticals, Inc. Expect to initiate Phase 1 development in mid-2024 to compare pharmacokinetics of subcutaneous form to intravenous form of ACU193 ...
Acumen Pharmaceuticals Inc (ABOS-Q) Quote - Press Release
NEWTON, Mass., Nov. 06, 2024 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS), a clinical-stage biopharmaceutical company developing a novel therapeutic that targets soluble amyloid ...
Acumen Pharmaceuticals, Inc. and Halozyme Enter Global Collaboration ...
Acumen intends to explore using ENHANZE® with ACU193 and plans to initiate Phase 1 development in human subjects in mid-2024 to compare the pharmacokinetics (PK) of a subcutaneous form of ACU193 ...
Similar Companies
Loading the latest forecasts...